Dianthus Therapeutics (DNTH) Stock Analysis

What Dianthus Therapeutics does

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Key metrics

ETFs linked to DNTH

Broad-market and Healthcare sector ETFs an investor holding Dianthus Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how DNTH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Dianthus Therapeutics?

Dianthus Therapeutics trades under the ticker DNTH on NASDAQ.

Which exchange is DNTH listed on?

DNTH is listed on NASDAQ.

What sector does Dianthus Therapeutics operate in?

Dianthus Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze DNTH in a portfolio?

PortView shows DNTH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.